Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Emily Hayes
Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.
Merck's KEYNOTE-061 gastric cancer study is the latest example of a checkpoint inhibitor failing in Phase III after accelerated approval.
Sponsors expect that if Venclexta demonstrates compelling early data in new indications – like acute myeloid leukemia and multiple myeloma – the US FDA will be willing to help speed access for patients.
Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.
Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.
A New England Journal of Medicine publication and editorial highlighted a small study of ten patients in which one infusion of Spark/Pfizer's SPK9001 gene therapy "nearly completely eliminated" the need for factor IX clotting products, saving $200,000 per patient per year.